AU717453B2 - Extraction, amplification and sequential hybridization of fungal cell DNA and process for detection of fungal cells in clinical material - Google Patents

Abstract

Detecting fungal cells in clinical material, comprises extracting fungal DNA from whole blood and detecting the extracted fungal DNA, and/or identifying the fungal species from the extracted DNA. Also claimed is identifying a fungal species, comprising preparing a test soln. contg. at least segments of the DNA of the species to be identified, and detecting nucleotide sequences characteristic of the species in the soln.. Also claimed are the oligonucleotide probes (I)-(VI), TCTGGGTAGC CATTTATGGC GAACCAGGAC (I), TTCTGGCTAA CCCCAAGTCC TTGTGGCTTG (II), GTCTTTCCTT CTGGCTAGCC TCGGGCGAAC (III), GTTGGCCGGT CCATCTTTCT GATGCGTACT (IV), TTTCCTTCTG GCTAGCCTTT TTGGCGAACC (V), and CATGGCCTTC ACTGGCTGTG GGGGGAACCA (VI).

Description

EXTRACTION, AMPLIFICATION AND SEQUENTIAL HYBRIDIZATION OF FUNGAL CELL DNA AND PROCESS FOR DETECTION OF FUNGAL CELLS IN CLINICAL MATERIAL The present invention generally relates to a process for detection of fungal cells in clinical material.

Such processes are known from practice, and are usually based on cultivation of fungal species from clinical material on adequate nutrient media.

The speed and sensitivity of identification are greatly affected by the cultivation, e.g. in Petri dishes, and detection on the basis of the colonies which have grown or not, particularly on account of the slow growth of the fungal species. An invasive fungal infection can thus often only be diagnosed by an extremely complicated biopsy of an organ or even only after the death of a patient.

The interest in a process for detection of fungal cells must be seen in relation to the fact that particularly over the past few years, fungal pathogens have become very important for immunosuppressed patients as significant nosocomial pathogens.

Invasive fungal infections have increased considerably following bone marrow transplantation (BMT), though also after liver, kidney, pancreas and heart or heart-lung transplantation. In 1994, for example, there was an accumulation of infections, particularly Aspergillus infections, in French BMT centers which resulted in closure of these centers for a number of months.

Apart from patients with organ transplants, patients suffering from cancer, particularly after chemotherapy or surgery, patients with burns and patients in surgical and neonatal intensive care units are being increasingly affected by invasive fungal pathogens. As soon as an organ system or even a number of organ systems are affected in these groups of patients, the mortality rate for these infectious complications rises to between 80 and 100-%.

The success of a therapy can only be improved in such cases through an early diagnosis. On account of the disadvantages associated with the standard detection methods mentioned above, there have been intensive attempts to permit an early, safe diagnosis of a systemic fungal infection.

Although new techniques based on molecular biology methods have already permitted a more sensitive diagnosis and thus partly an earlier detection and treatment of the infectious diseases for a number of other pathogens, this has as yet been impossible for fungal pathogens.

However, the publication "Detection of various fungal pathogens in blood samples" in: EBMT 1995, Vol. 15, Suppl. 2, March 1995, Abstract Book, Abstract 432, P. 103, already describes the amplification of a DNA segment of a fungal gene using the PCR method so as to identify a number of fungal pathogens in blood.

Through an additional hybridization with species-specific oligonucleotides, a differentiation between various fungal strains was also possible.

The most important problems during the detection of fungal infections using molecular biology techniques are caused by the very complex composition of the fungal cell walls, which have made time-consuming and expensive extraction methods necessary until now.

A further problem is the fact that an increasing number of fungal species can trigger dangerous infections in immunosuppressed patients, leading to the necessity of the recording and detection of a whole range of different fungal species and strains in these patients. Since therapies differ for various fungal species it is necessary to not only record all fungal species but also to differentiate between and identify these species.

In view of the above, it is an object of the present invention to improve the process mentioned above to permit an early diagnosis of a fungal infection.

-7 NT O 4 The process should be as quick and easy as possible, it should record as many fungal species as possible and it should also be able to identify these in a further stage of development.

The process to detect fungal pathogens in clinical material found in accordance with the invention comprises the following steps: extraction of fungal DNA from whole blood; and detection of extracted fungal DNA.

By abandoning the traditional cultivation of fungal species from clinical material and turning to the fungal DNA itself a process has been developed which permits a very early detection of fungal infections with a high sensitivity through detection of the fungal-specific DNA. Since the detection can be performed on the DNA level, at least partially highly sensitive, well established and fast processes can be used, leading to great advantages over known methods in terms of sensitivity and speed. It should be remembered that the release and purification of the fungal DNA must be performed not only quickly but also almost completely and relatively purely to guarantee a high sensitivity and permit a rapid diagnosis.

Moreover, the new process should be sensitive for a number of fungal species, and the fungal species should also be identified in the least possible procedural steps.

This further object is achieved in the aforementioned new process through the following procedural step which is carried out in addition to or in place of procedural step determination of the fungal species from the extracted fungal DNA.

This process has the further advantage that the diagnosis of the specific fungal infection on the DNA level can be carried out very quickly and displays a high specificity, since, for example, known sequencing processes can be used.

A number of problems had to be overcome in the individual steps of the new process, some of which arose from the composition of the fungal cell wall and from the fact that a large number of the fungal cells are not freely dissolved in whole blood but are located in a number of blood cell populations following phagocytosis, especially in granulocytes and macrophages.

The object of the present application is thus also the isolated first step in the process, namely the extraction of fungal

DNA

from whole blood. Although this process can be used advantageously in diagnostics to detect a fungal infection in a patient, it can also be employed wherever fungal DNA is required for other further processing.

Using the new process for example, fungal DNA can be extracted from the blood of animals which have been specifically infected by the fungal species in question. DNA probes can be cut out from the fungal DNA obtained in this manner which can then be PA used for detection reactions or be cloned in plasmids. Applica-

-A

~'vT 6 tions throughout the whole field of basic research, diagnostics, therapy, industrial gene technology, etc. are conceivable.

The process for the extraction of fungal DNA should be able to reliably extract fungal DNA even with very small quantities of fungi in whole blood. Furthermore, this step of the process should be able to be performed quickly and easily so that it can be employed in everyday work in hospitals by trained personnel.

This object is achieved in accordance with the invention in that the step of extracting fungal DNA from whole blood comprises the steps of: a) isolation of predominantly intact fungal cells from whole blood; and b) extraction of DNA from the isolated fungal cells.

The object of the invention is completely achieved in this manner. The new process now comprises two stages, comprising isolation of fungal cells from whole blood in the first step and then extracting of DNA from these isolated fungal cells in the second step so that the extracted DNA can be used to detect and if necessary identify fungal infections. This two-stage process above all improves the specificity since only small amounts of any interfering other DNA are present in the second step of the process.

7 It is preferred if the process comprises the following procedural steps: al) disintegration of the blood cells in whole blood; a2) isolation of predominantly intact fungal cells from cellular DNA; bl) disintegration of isolated fungal cells; and b2) isolation of fungal

DNA.

This leads to a very rapid and safe separation of fungal

DNA

from cellular DNA. The cellular DNA is released in this initial solution by lysis of blood cells in whole blood so that the fungal cells which up to then have not been, or at least have not been completely disintegrated by the preceding disintegration process, can be separated from the free cellular DNA in a quick and easy process, e.g. through centrifugation. During the subsequent lysis of the fungal cells isolated in this manner it can be safely assumed that there is no or only an insignificant amount of cellular DNA in the solution. The disintegration of the blood cells in step al) must thus be carried out in such a way that the fungal cells are not yet lysed. Since the fungal cell wall is much more complex than the cell wall of blood cells this can be ensured through adequate careful disintegration processes.

The procedural step al) has a further advantage, namely that it releases any phagocyted fungi so that very small quantities of ngi can still be extracted from the whole blood, particularly 8 for diagnostic purposes. With the new process it is no longer necessary for at least a few fungal cells to be freely dissolved in whole blood, it is more than sufficient if a few fungal cells are present after phagocytosis, e.g. in granulocytes or macrophages.

It is preferred if the following steps are carried out in step a): al.l) lysis of the erythrocytes by osmotic hemolysis; al.2) enzymatic disintegration of the leukocytes; and a2.1) centrifugation of the whole blood treated in this manner and use of the pellet in the next procedural steps.

The advantage here is that although the blood cells are reliably dissolved in steps al.l) and al.2), the fungal cells themselves are not damaged yet. The subsequent centrifugation then ensures a very safe separation between the released cellular DNA and cell fragments of the blood cells on the one hand and the still predominantly intact fungal cells on the other. This also ensures that no fungal DNA is lost since fungal DNA is still present in the fungal cells in the pellet. Summing up, the advantages of the aforementioned steps are thus that on the one hand even minimal concentrations of fungal cells can be detected and on the other the isolated fungal DNA is at most only slightly contaminated with cellular DNA, permitting a high sensitivity and specificity in the subsequent diagnostic steps since the ratio of fungal to cellular DNA has been significantly improved in favor of fungal DNA.

In a further development it is then preferred if the following steps are carried out in step b): bl.l) alkaline lysis and enzymatic treatment of the fungal cells.

It could be shown that this simple procedural step permits a safe disintegration of the fungal cells which are recovered from the pellet in procedural step a2.1).

It is furthermore preferable if the lysis of the erythrocytes in step al.l) is carried out using a hypotonic solution, preferably with a final concentration of approx. 10 mM Tris pH 7.6, mM MgCl 2 and 10 mM NaCI, and if in step al.2) the enzymatic digestion of the leukocytes is carried out in a solution having a final concentration of 200 pg/ml proteinase K, 10 mM Tris pH 7.6, 10 mM EDTA pH 8.0, 50 mM NaCl and 0,2 SDS.

In a further development the solution from step al.2) is incubated for 100-140 min, preferably 120 min, at 60-70 0 C, preferably at 65 0

C.

It has been found that in this way the blood cells can be reliably and completely disintegrated without damaging the fungal cells so that after these procedural steps both the fungal cells freely in solution and the phagocyted fungal cells in the initial blood remain relatively undamaged and can be separated by centrifugation without losing their DNA.

It is furthermore preferable if step bl.l) comprises the following steps: incubation of the fungal cells present in the pellet from step a2.1) at 90-98 0 C, preferably 95 for 5-15 min, preferably 10 min., in a solution with 50 mM NaOH, neutralization with 1 M Tris-HCl pH S enzymatic treatment with zymolyase for 50-70 min, preferably 60 min at 30-40 0 C, preferably 37 0

C,

protein denaturation by incubation with Tris/EDTA at 60-70°C, preferably 65 0 C, for 10-30 min, preferably min.

It has been found that these procedural steps permit a safe disintegration of the fungal cells with a subsequent complete release of fungal DNA so that the fungal DNA is then in solution and can be isolated from the cell fragments of the fungal cells.

It is preferred if in this connection step b2) comprises the following steps: protein precipitation with 5 M potassium acetate, and DNA precipitation of the supernatant in ice-cold isopropanol.

These procedural steps are very easy to be carried out, the protein is firstly precipitated by adding potassium acetate, the supernatant then removed and mixed with ice-cold isopropanol so that the DNA is precipitated. The precipitated DNA can then be used in the further procedural steps, i.e. to detect and identify a fungal infection.

Summing up the procedure as described up to now, the first advantage is that the fungal species can be generally detected on the basis of their DNA and can then be specifically identified.

The fungal DNA is not extracted directly from the whole blood, rather there is firstly a separation of the fungal cells from cellular DNA to improve the sensitivity and specificity of the detection. In other words, if only very few fungal cells are present in the whole blood the very small quantity of fungal DNA extracted from this could be detected against the background of cellular DNA present in a very high concentration, so that the separation mentioned above leads to great advantages in terms of sensitivity.

A further advantage of the new process is that phagocyted fungal cells are also available for detection purposes since the blood cells of the whole blood are initially disintegrated without damaging the fungal cells, irrespective of whether these are in solution or phagocyted. The fungal cells are only disintegrated following separation of the fungal cells from the cellular DNA and remaining cell debris of the blood cells. The method employed here ensures a complete disintegration with no damage to the fungal DNA despite the lightly complex fungal cell walls.

C A T \i~;vT o%~o The object of the present invention is also a kit to carry out the process described above. Such a kit can contain a set of all basic solutions which are required for the aforementioned procedural steps. However, it is also possible to include in this kit only those basic solutions normally not found in a laboratory, e.g. the Tris buffer is dispensible, though at least the proteinase K and zymolyase are present in the kit.

The object of the present application is also the second step of the process, either isolated or in combination with the first step of the process described above, i.e. the detection of extracted fungal DNA. The fungal DNA to be detected is hereby preferably extracted and isolated as described above.

However, it is also possible to obtain the fungal DNA by suitable density gradient centrifugation, specific precipitation steps with DNA probes, etc.

In all of these cases it is desirable to detect whether fungal DNA is actually present in that initial solution for further use.

Although the fungal DNA can be advantageously employed for the diagnosis of fungal infections, it can also be used differently. The fungal DNA can be obtained from agar plates or from the blood of animals which have been specifically infected with the fungal species in question. DNA probes can be cleaved from the fungal DNA obtained in this manner which can then be used for detection reactions or cloned in plasmids. Applications throughout the whole field of basic research, diagnostics, therapy, industrial gene technology, etc. are conceivable.

The new detection step should permit the recording of a number of various fungal species, even in low concentrations, in the initial solution in one single process so that it is possible to say whether there is a fungal infection at all very quickly and at an early stage in the diagnosis. Moreover, the new process should be able to be performed quickly and easily so that it can be employed in everyday work in hospitals by trained personnel.

The object is achieved in accordance with the invention in that the step to detect the extracted fungal DNA comprises the following steps: c) amplification of at least a segment of the isolated fungal DNA; and d) detection of the amplification product.

There are a number of standard methods with which even small amounts of an isolated DNA can initially be amplified and then detected. These methods are highly specific and very sensitive so that they provide the desired features for diagnosis, therapy, industrial gene technology, etc. Furthermore, these methods can be performed by trained personnel.

The amplification can be carried out either by PCR, cloning, DNA-dependent DNA-polymerases, etc., and the detection can be carried out by gel electrophoresis, optical density, staining with markers which bind specifically to nucleic acid, etc.

KRAI

14 In a further development the amplification is carried out by means of a polymerase chain reaction (PCR) using two primers which bind to the DNA of a number of different fungal species, preferably to the fungal gene for the 18ssu-rRNA.

The advantage here is that a simple and in the meantime established method can be used to produce adequate amounts of DNA which is then easily detected, though the DNA can also further be used to identify the corresponding fungal species.

It is preferred if the nucleotide sequences SEQ ID-No: 1 and SEQ ID-No: 2 from the enclosed sequence listing are used as primers in step c).

The inventor of the present application surprisingly found that these two nucleotide sequences can be used as primers for various clinically relevant fungal species. The use of these two primers in the PCR reaction produces amplification products having a length of approx. 500 base-pairs, and are thus easy to be further processed since they can be easily detected by gel electrophoresis. In this way there is an identical detection process for all pathogenic fungal species since it was found that the two primer sequences bind to the various fungal DNAs.

It is preferred if the polymerase chain reaction is carried out with the following cycle: cl) denaturation for 0.3-1 min, preferably for 0.5 min, at 90-96 0 C, preferably at 94 0

C;

c2) hybridization for 0.5-1.5 min, preferably for 1 min, at 58-64 0 C, preferably at 62 0

C;

c3) extension for 1.5-2.5 min, preferably for 2 min, at 68-75°C, preferably at 72 0

C.

It is preferred if a denaturation step of 5-9 min, preferably 3 min, at 90-96°C, preferably 94 0 C, is carried out before the start of the cycle steps.

It was found that the PCR is very reproducible and above all highly specific under the aforementioned conditions so that it can be ensured that the amplification products are in fact segments of the original fungal DNA.

It is furthermore preferred if in step d) the amplification products are detected by gel electrophoresis, preferably on an agarose gel, and are preferably stained with ethidium bromide.

The advantage of this is that a known and well established detection method is used to show that amplification products which indicate a fungal infection are in fact produced by the PCR reaction.

It is further preferred if a DNA sequence from the fungal gene for the 18ssu-rRNA is amplified.

The inventor of the present application found that this fungal gene displays a specific sequence segment in the various fungal trains and species which on the one hand is flanked by two iing regions for primers which are identical for all fungal strains and species, though on the other hand the sequence of this segment differs to such an extent for the various fungal strains and species that it can be used to detect individual fungal species and strains.

The invention further relates to the nucleotide sequences SEQ ID-No: 1 and SEQ ID-No: 2 from the enclosed sequence listing.

It is preferable if these two nucleotide sequences are used to amplify a segment of fungal DNA.

The invention also relates to a kit to detect fungal DNA in a test solution, and the kit contains primers for a polymerase chain reaction binding to the DNA of a number of fungal species. The kit preferably contains the nucleotide sequences SEQ ID-No: 1 and SEQ ID-No: 2 from the sequence listing as primers.

The invention also relates to a kit to carry out the process described above.

The advantage of such a kit is that all necessary solutions, and in particular the necessary primers, can be put together so that they can be used for routine procedures. Thus these new kits can be used in everyday laboratory work to detect fungal species in test solutions. Moreover, this kit can be used to amplify certain segments of the proven fungal species which can then be used for further identification processes, for example.

The object of the present application is also the third step of the process, either isolated or in combination with the first and the second steps of the process described above, i.e. the identification of the fungal species using the extracted and detected fungal DNA.

The fungal identification of the species should be able to be carried out quickly and easily for diagnostic purposes so that it can be employed in everyday work in hospitals by trained personnel.

This object is achieved in accordance with the invention inasmuch as the following step is carried out: e) identification of the nucleotide sequence sections of the DNA contained in the test solution characterizing the fungal species.

Since the detection process is carried out on the DNA level it is sufficient if certain segments of the fungal DNA are identified provided these segments are specific for the respective fungal species. Standard methods can be used by sequencing at least a part of the amplification product, investigating the melting behavior of the double strands, etc.

These processes can generally be performed quickly and easily so that they can also be carried out by trained personnel.

It is preferred if the fungal DNA or segments of the fungal DNA are hybridized with DNA probes which are specific for defined fungal strains and/or species in step the test of successful hybridization leading to an identification of the fungal species.

The advantage of this is that a very fast and simple hybridization process is used for identification. Specific probes are used which are specific to the respective fungal species so that they bind exclusively to the amplified segments of these fungal species. Such processes can be carried out on gels, for example, the hybrids being shown by staining. A further process consists of exploiting the optically different behaviors of single strands and double-stranded regions, e.g. optical density, dichroism or similar features.

It is furthermore preferred if the probes are labeled with digoxigenin for testing of successful hybridization and if the hybrids are detected using the Southern-Blot method, for instance.

This step further simplifies the process, the probes themselves are already provided with the corresponding marker which shows the formation of hybrids following hybridization, preferably by visually detectable dye reactions, using a well-known method.

It is preferred if one or more of the nucleotide sequences SEQ ID-No: 3 to SEQ ID-No: 8 from the enclosed sequence listing are used as DNA probes, the DNA probes being preferably used sequentially in the sequence SEQ ID-No: 3, SEQ ID-No: 8, SEQ ID-No: 6, SEQ ID-No: 7, SEQ ID-No: 4 and SEQ ID-No: 5 and if the respective hybridization is tested.

The individual fungal species can be tested in the order of their frequency by the sequential hybridization, thus significantly accelerating the detection process.

The invention further relates to the nucleotide sequences SEQ ID-No: 3 SEQ ID-No: 8 from the enclosed sequence listing.

The invention further relates to the use of one or more of these nucleotide sequences as DNA probes to identify fungal species.

The advantage here is that the 6 specified nucleotide sequences can specifically discriminate between all clinically relevant fungal species.

The nucleotide sequence SEQ ID-No: 3 detects the fungal species Candida albicans, SEQ ID-No: 4 detects Candida glabrata,

SEQ

ID-No: 5 detects Candida krusei, SEQ ID-No: 6 detects Candida tropicalis, SEQ ID-No: 7 detects Candida parapsilosis and SEQ ID-No: 8 detects fungal species belonging to the strain Aspergillus, particularly A. fumigatus, A. flavus, A. versiculor,

A.

niger, A. nidulans and A. terreus.

The invention further relates to a kit to identify fungal species which contains DNA probes which hybridize to specific nucleotide sequence sections of the DNA of the respective fungal species. The kit preferably contains one or more of the nucleotide sequences SEQ ID-No: 3 SEQ ID-No: 8 from the enclosed sequence listing as DNA probes.

The invention further relates to a kit to carry out the process described above.

The advantage of this is that such a kit can be provided with ither only the DNA probes or additionally with the adequate ,V)'VT additional solutions so that all primary solutions, etc. necessary for everyday laboratory work can be taken directly from this kit. This considerably simplifies the detection or the identification of the respective fungal species since the individual primary solutions no longer have to be produced separately in the laboratory. However, it is also possible to include only the probes and possibly the primers and enzyme/primary solutions for the polymerase chain reaction in this kit so that apart from this, standard primary solutions can be used.

A process for detection of fungal cells in whole blood comprising the steps detailed above in an advantageous manner comprises the following steps: isolation of predominantly intact fungal cells from whole blood, extraction of DNA from the isolated fungal cells, amplification of at least one segment of the isolated fungal DNA, preferably of at least one segment of the fungal gene for the 18ssu-rRNA, detection of the amplification products according to a yes/no decision, and assigning the amplification products to individual fungal species by hybridizing them with DNA probes being specific for defined fungal strains and/or species.

One of the main advantages of this summarized process is that only one amplification step is required amplifying a segment of the fungal DNA, preferably a segment of the fungal gene for the 18ssu-rRNA in such a way that the amplification products can be used for the yes/nor decision as well for the determination of the fungal species. The inventor of the present application has found that the fungal gene for the 18ssu-rRNA can at least partly be flanked by two primers being identical for all fungal species of interest on the one hand, the amplicon being different for the various fungal species on the other hand, so that it can be hybridized with different probes characteristic for the fungal species.

A single amplification step therefore is sufficient to answer the question whether there is a fungal infection at all and to answer the question which fungal species is concerned. The process is therefore extremely simple and can be easily carried out, specialized knowledge is not required, so that it can be carried out even by trained personnel.

Further advantages can be taken from the following description.

It is understood that the aforementioned features and those to be explained in the following can be used not only in the specified combinations but also in other combinations or alone without going beyond the scope of the present invention.

Examples of the performance of the individual procedural steps and the use of the process within the scope of a program of a clinical test program are quoted in the following description.

A particular advantage of the new process is the fact that it is performed using whole blood, i.e. no biopsy is required and no serum which first has to be produced is used. The fungal cells are firstly separated from the cellular DNA in the whole blood. This is necessary for the fungal DNA, which may only be present in very small quantities, not having to be detected against the background of the much higher concentration of cellular DNA. This also increases the specificity of the detection process. For this purpose the erythrocytes are initially lysed by osmotic hemolysis and the leukocytes are then enzymatically digested. These two procedural steps are selected in such a way that the fungal cells themselves are not yet damaged and that any phagocyted fungal cells are released undamaged so that they are also available for subsequent detection.

Example 1: Lysis of erythrocytes by osmotic hemolysis.

The lysis of the erythrocytes is carried out using a hypotonic solution. The following buffer having the following final concentration is used: Tris pH 7.6 10 mM MgCI 2 5 mM NaCl 10 mM The solution is incubated for 10 min at room temperature and then centrifuged.

An amount of 3 ml whole blood is sufficient for the first step.

Example 2: Enzymatic digestion of leukocytes The leukocytes, which may contain fungal cells, are carefully disintegrated by enzymatically digesting the cells with proteinase K (20 pg/ml) obtained from Boehringer Mannheim, in the following buffer containing the following final concentrations, in which the pellet from example 1 is resuspended: Tris pH 7.6 EDTA pH 8.0 NaCl

SDS

Proteinase

K

10 mM 10 mM 50 mM 0.2 200 pg/ml This buffer is incubated for two hours at 65 0

C.

Example 3: Separation of predominantly intact cells, above all from cellular DNA fungal Once the blood cells have been disintegrated the way explained in examples 1 and 2, so that the cellular DNA has been released, centrifugation is carried out at 5000 rpm, leading to a considerable loss of cellular DNA since DNA does not sediment at this centrifugation speed.

The sediment now contains all free or released fungal cells which are resuspended in a buffer (Aqua bidest) for further processing.

Example 4: Disintegration of the fungal cells The fungal cells are now lysed in alkaline and enzymatically treated to release the fungal DNA.

Firstly an alkaline lysis is carried out using 200 ml 50 mM NaOH for 10 min at 95 0

C.

This step is followed by a neutralization step using 1 M Tris-HCl pH 500 1p Zymolyase from Sigma (300 pg/ml) are then added and the solution is incubated for 60 min at 37 0 C to enzymatically digest the fungal cells.

500 pl Tris/EDTA and 50 p1 10 SDS solution are then added and the solution is incubated at 65°C for 20 min to denature the protein.

Example 5: Isolation of fungal DNA Fungal cell debris and free fungal DNA, which has next to be isolated, are present in this solution.

Firstly a protein precipitation is carried out using 5 M potassium acetate, after which the supernatant is removed and the DNA precipitated by adding ice-cold isopropanol. The precipitation product is then used for the further procedural steps.

The procedural steps specified in examples 1 5 permit the extraction of fungal DNA in a highly selective way from whole blood which is then available as a precipitate and is only slightly contaminated with cellular DNA, so that the following detection can be carried out in a very sensitive way and with a high specificity.

Example 6: Amplification of a fungus specific DNA segment In this procedural step it will initially be shown whether fungal DNA is at all present in the precipitate obtained from the procedural step of example 5. This step makes use of the fact that the DNA sequences shown in the sequence listing as SEQ ID-No: 1 and SEQ ID-No.: 2 bind specifically to binding sites on the fungal gene for the 18ssu-rRNA of numerous fungal strains and species.

The inventor of the present application has found that this fungal gene in the various fungal strains and species displays a specific sequence segment which on the one hand is flanked by two binding regions for primers which are identical for all fungal strains and species, though on the other hand the sequence of this segment differs to such an extent for the various fungal strains and species that it can be used to detect individual fungal species and strains.

The DNA sequence SEQ ID-No: 1 binds to the sense strand, whereas the DNA sequence SEQ ID-No: 2 binds to the anti-sense strand, the distance between the two binding sites being approx. 500 base-pairs. These two DNA sequences SEQ ID-No: 1 and SEQ ID-No: 2 are thus suitable as primers for a polymerase RA 4 i~ir chain reaction (PCR), which results in the production of amplification products (amplicon) with a length of approx. 500 base-pairs.

The position of the primers and length of the respective amplicon are shown in the following Table 1.

Table 1: Amplicons obtained from fungal pathogens Fungal species C. albicans C. glabrata C. krusei C. tropicalis C. parapsilosis A. fumigatus A. niger A. flavus A. terreus A. nidulans Binding sites of primers Forward primer bp544-563 bp546-565 bp535-554 bp544-563 bp544-563 bp544-563 bp483-502 bp483-502 bp481-500 bp581-500 Reverse primer bpl033-1014 bpl047-1028 bpl016-997 bpl030-1011 bpl033-1014 bpl046-1027 bp986-967 bp985-966 bp984-965 bp984-965 Length of amplicon bp490 bp502 bp482 bp487 bp490 bp503 bp503 bp502 bp503 bp503 Using the two primers SEQ ID-No: 1 and SEQ ID-No: 2 the production of sufficient amounts of amplicons of approx. 500 base-pairs for all relevant fungal species of the Candida and Aspergillus strains in the PCR procedure can be obtained.

The PCR conditions are as follows: Buffer (501p): mM Tris pH 9.6 mM NaCl mM MgCl 2 0.2 mg/ml BSA Polymerase each 0.5 mM nucleotide each 100 pM primer Initial denaturation: Cycle denaturation: Annealing: Extension: Terminal extension: Number of cycles: 3 min at 94 0

C

0.5 min at 94 0

C

1 min at 62 0

C

2 min at 72 0

C

5 min at 72 0

C

34 The high magnesium concentration in the buffer permits a high specificity of the polymerase which can work at its optimum temperature of 72 0 C in the extension step.

A total of 40 strains of Candida albicans, 10 Candida tropicalis, 6 Candida parapsilosis, 11 Candida glabrata, 8 Candida krusei, 8 Aspergillus fumigatus, 6 Aspergillus flavus, 5 Aspergillus terreus, 7 Aspergillus niger, 5 Aspergillus nidulans and 3 Aspergillus versiculor could be successfully amplified with these primers.

Example 7: Detection of amplification products from example 6 In the next step it is shown whether DNA segments with a length of approx. 500 base pairs are actually amplified during the PCR reaction in example 6. The detection of the fungus specific DNA segments is carried out by ethidium bromide staining of the specific bands in a 2% agarose gel.

R\ 1t If the specific band is detected here a fungal infection can be assumed since the primers SEQ ID-No: 1 and SEQ ID-No: 2 bind to all the aforementioned fungal strains. Thus, if fungal DNA is extracted during the procedural steps of examples 1 5, it is amplified by the PCR step of example 6 to such an extent that it can be detected by ethidium bromide staining.

Example 8: Classification of the amplification products from example 6 in individual fungal species The fungal infection already proven in step 7 next has to be specified more precisely for a specific therapy. A further advantage of the PCR step from example 6 now becomes apparent.

Enough fungus-specific DNA segments have been produced for further detection methods for a determination of the fungal species.

The nucleotide sequences SEQ ID-No: 3 to SEQ ID-No: 8 specified in the sequence listing are used here; these serve as species-specific probes which hybridize specifically with a sequence section of the DNA segment produced in example 6.

It has been found that probe SEQ ID-No: 3 hybridizes with Candida albicans, SEQ ID-No: 4 with Candida glabrata, SEQ ID-No: with Candida krusei, SEQ ID-No: 6 with Candida tropicalis,

SEQ

ID-No: 7 with Candida parapsilosis and SEQ ID-No: 8 with Aspergillus fumigatus, A. flavus, A. versiculor, A. niger, A. nidulans and A. terreus. The nucleotide sequence SEQ ID-No: 8 is thus a general Aspergillus probe whereas the nucleotide sequences SEQ ID-No: 3 SEQ ID-No: 5 can discriminate between 1upgal species of the Candida strain.

In order to be able to prove the successful hybridization, the probes are labeled with the Transferase kit from Boehringer Mannheim, the detection being carried out according to the Southern-Blot method using the known color reactions.

A sequential hybridization is carried out with these probes which is graduated according to the frequency of the individual fungal species so that hybridization starts with SEQ ID-No: 3 albicans), then SEQ ID-No: 8 (Aspergillus), SEQ ID-No: 6 tropicalis), SEQ ID-No.: 7 parapsilosis), SEQ ID-No.: 4 glabrata) and finally SEQ ID-No.: 5 krusei).

In this way it is possible to identify the fungal species according to the amplification products produced in step example 6 and to then initiate a specific therapy.

Example 9: Detection of fungal cells disseminated in blood With the aid of specific amplification and sequential hybridization it was possible to successfully detect fungal species with a sensitivity of 1 3 fungal cells. Through a dissemination of fungal species in blood samples it could be proven that the aforementioned process reaches a sensitivity of one so-called CFU (colony forming unit)/ml blood. This detection limit is far below that which can be expected for a clinically relevant fungal dissemination in blood.

Example 10: Program of clinical tests In a large-scale program of clinical tests a high specificity of the new process could be shown during the analysis of 165 blood samples from 65 healthy test persons. All 165 blood samples remained negative.

94 immunosuppressed patients with unclear fever were then tested for the presence of a fungal infection. Of 65 patients having no invasive fungal infection, over 200 blood samples (apart from one exception) were also negative.

On the other hand, all 25 patients having an invasive fungal infection could be identified to be positive already within the first week. Moreover, the causative fungal pathogen could be classified for all patients.

SEQUENCE LISTING GENERAL INFORMATION:

APPLICANT:

NAME: Eberhard-Karls-Universitat Tubingen, UniversitAtsklinikum STREET: Geissweg 3 CITY: TUbingen COUNTRY: Deutschland POSTAL CODE: D-72076 TELEPHONE: 07071-29-1 TELEFAX: 07071-293966 TITLE OF INVENTION: Extraction of fungal cell DNA NUMBER OF SEQUENCES: 8 COMPUTERREADABLE

FORM:

MEDIUM TYPE: (follows)

COMPUTER:

OPERATING SYSTEM:

SOFTWARE:

INFORMATION FOR SEQ ID-NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL: YES SEQUENCE DESCRIPTION: SEQ ID-NO:1: ATTGGAGGGC AAGTCTGGTG INFORMATION FOR SEQ ID-NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 20 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL: YES SEQUENCE DESCRIPTION: SEQ ID-NO:2: CCGATCCCTA GTCGGCATAG INFORMATION FOR SEQ ID-NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL: YES SEQUENCE DESCRIPTION: SEQ ID-NO:3: TCTGGGTAGC CATTTATGGC GAACCAGGAC INFORMATION FOR SEQ ID-NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL: YES SEQUENCE DESCRIPTION: SEQ ID-NO:4: TTCTGGCTAA CCCCAAGTCC TTGTGGCTTG INFORMATION FOR SEQ SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL:

YES

SEQUENCE DESCRIPTION: SEQ GTCTTTCCTT CTGGCTAGCC TCGGGCGAAC INFORMATION FOR SEQ ID-NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL: YES SEQUENCE DESCRIPTION: SEQ ID-NO:6: GTTGGCCGGT CCATCTTTCT GATGCGTACT INFORMATION FOR SEQ ID-NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL:

YES

SEQUENCE DESCRIPTION: SEQ ID-NO:7: k TTTCCTTCTG GCTAGCCTTT TTGGCGAACC 34 INFORMATION FOR SEQ ID-NO:8: SEQUENCE CHARACTERISTICS: LENGTH: 30 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear HYPOTHETICAL: YES SEQUENCE DESCRIPTION: SEQ ID-NO:8: CATGGCCTTC ACTGGCTGTG GGGGGAACCA

Claims (13)

1. Method for detection of fungal DNA in clinical mate- rial by extraction of fungal DNA from whole blood, including the steps of: a) isolation of predominantly intact fungal cells from whole blood, b) extraction of DNA from the isolated fungal cells by means of bl) disintegration of isolated fungal cells, and b2) isolation of fungal DNA, wherein step a) further comprises the steps of: al) disintegration of the blood cells contained in the whole blood; a2) isolation of predominantly intact fungal cells from cellular DNA.

2. Method according to claim 1, wherein step a) further includes the steps of: al.l) lysis of the erythrocytes by osmotic hemolysis; al.2) enzymatic digestion of the leukocytes; and a2.1) centrifugation of the whole blood treated in this manner and use of the pellets in the next procedural step.

3. Method according to claim 2, wherein the lysis of the erythrocytes in step al.l) is carried out using a hypotonic solution and a detergent, preferably with a final concentration of 10 mM Tris pH 7.6, 5 mM MgC 2 1 and 10 mM NaC1. r,.

4. Method according to claim 2 or 3, wherein in step al.2) the enzymatic digestion of the leukocytes is carried out in a solution with a final concentration of 200 pg/ml protein- ase K, 10 mM Tris pH 7.6, 10 mM EDTA pH 8.0, 50 mM NaCl and 0,2 SDS. Method according to claim 4, wherein the solution is incubated for 100-140 min, preferably 120 min, at 60-70 0 C, preferably at 065 C.

6. Method according to anyone of claims 1 5, wherein step bl) includes the following step: bl.l) alkaline lysis and enzymatic treatment of the fungal cells.

7. Method according to claim 6, wherein step bl.l) in- cludes the following steps: incubation of the fungal cells present in the pellet from step a2.1) at 90-95 0 C, preferably 950, for 5-15 min, pref- erably 10 min, in a solution with 50 mM NaOH, neutralization with 1 M Tris-HCl pH enzymatic treatment with Zymolyase for 50-70 min, preferably 60 min at 30-40 0 C, preferably 37 0 C, protein denaturation through incubation with Tris/EDTA at 60-70 0 C, preferably 65 0 C, for 10-30 min, prefera- bly 20 min.

8. Method according to claim 6 or 7, wherein step b2) includes the following steps: protein precipitation with 5 M potassium acetate, DNA precipitation of the supernatant in ice-cold isopropanol.

9. Kit to carry out the process according to any of claims 1 8. Nucleotide sequence SEQ ID-No: 1 from the enclosed sequence listing.

11. Nucleotide sequence SEQ ID-No: 2 from the enclosed S* sequence listing.

12. Use of the nucleotide sequences according to claims and 11 as primers for the amplification of a segment of the fungal gene for 18ssu-rRNA of a number of fungal species by po- lymerase chain reaction.

13. Method for the detection of fungal cells in a test solution, preferably to be carried out in connection with the method according to one of claims 1 8, including the steps of: c) amplification of at least one segment of the fungal DNA to be detected by polymerase chain reaction, and d) if necessary, detection of the amplification prod- ucts, wherein in step c) the nucleotide sequences SEQ ID-No: 1 and SEQ ID-No: 2 from the enclosed sequence listing are used as primers.

14. Method according to claim 13, wherein in step c) the polymerase chain reaction is carried out with the following cy- cle: cl) denaturation for 0.3-1 min, preferably for 0.5 min, at 90-96*C, preferably at 94*C; c2) hybridization for'0.5-1.5 min, preferably for 1 min, at 58-64 0 C, preferably at 62 0 C; c3) extension for 1.5-2.5 min, preferably for 2 min, at

68-75°C, preferably at 72 0 C. Method according to claim 14, wherein a denaturation step of 5-9 min, preferably 3 min, at 90-96*C, preferably 94°C, is carried out before the start of the cycle steps. 16. Method according to claims 13 15, wherein in step d) the amplification products are detected using gel- electrophoresis, preferably on an agarose gel, and being stained preferably using ethidium bromide. 9 17. Kit for detection of fungal DNA in a test solution, including the nucleotide sequences from claims 10 and 11 as primers. 18. A kit when used to carry out the method according to one of claims 1 to 8 and 13 to 16. 19. Nucleotide sequence SEQ ID-No: 3 from the enclosed sequence listing. Nucleotide sequence SEQ TD-No: 4 from the enclosed g,,s equence listing. 21. Nucleotide sequence SEQ ID-No: 5 from the enclosed sequence listing. 22. Nucleotide sequence SEQ ID-No: 6 from the enclosed sequence listing. 23. Nucleotide sequence SEQ ID-No: 7 from the enclosed sequence listing. 24. Nucleotide sequence SEQ ID-No: 8 from the enclosed sequence listing. 25. Use of one or more of the nucleotide sequences from claims 19 24 as DNA probes for identification of fungal spe- cies. 9. 9. *9 9r 26. tect the 27. tect the 28. tect the 29. tect the tect the Use of the nucleotide sequence from claim 19 to de- fungal species Candida albicans. Use of the nucleotide sequence from claim 20 to de- fungal species Candida glabrata. Use of the nucleotide sequence from claim 21 -to de- fungal species Candida krusei. Use of the nucleotide sequence from claim 22 to de- fungal species Candida tropicalis. Use of the nucleotide sequence from claim 23 to de- fungal species Candida parapsilosis. 31. Use of the nucleotide sequence from claim 24 to de- tect the fungal species from the strain Aspergillus. 32. Method for identification of fungal species, pref- erably to be carried out in connection with the method accord- ing to one of claims 8 or 13 16, including the additional step: e) determination of nucleotide sequence segments of the DNA contained in the test solution being characteristic for the fungal species, wherein in step e) the fungal DNA or segments of the fungal DNA, which may have been amplified before according to step c), are hybridized with DNA probes being specific for certain fun- gal strains and/or species, and wherein the test of successful hybridization leads to identification of the fungal species, S. wherein one or more of the nucleotide sequences SEQ ID-No: 3 to SEQ ID-No: 8 from the enclosed sequence listing are used as DNA probes. 33. Method according to claim 32, wherein the probes are labeled with dioxygenin and the hybrids are detected, e.g. by the Southern-Blot method for testing of successful hybridiza- tion. 34. Method according to claim 32 or 33, wherein the DNA probes are used in sequential order, preferably in the follow- ing order: SEQ ID-No: 3, SEQ ID-No: 8, SEQ ID-No: 6, SEQ ID-No: 7, SEQ ID-No: 4 and SEQ ID-No: 5 and that the respective hy- bridization is tested. Kit for identification of fungal species, including one or more of the nucleotide sequences according to claims 19 24 as DNA probes. 36. Method for detection of fungal cells in whole blood, including the steps of: isolation of predominantly intact fungal cells from the whole blood, extraction of DNA from the isolated fungal cells, amplification of at least one segment of the ex- tracted fungal DNA, this being a segment of the fungal gene for the 18ssu-rRNA using the nucleotide sequences SEQ ID-No: 1 and 2 from the enclosed sequence listing, detection of the amplification products by way of a yes/no decision, and classification of the amplification products for single fungal species by hybridization with one or more of the nucleotide sequences SEQ ID-No: 3 8 as DNA probes. S37. A kit when used to carry out the method according to claim 36. DATED THIS 2ND DAY OF MARCH 1998 EBERHARD-KARLS-UNIVERSITAT TUBINGEN WATERMARK PATENT TRADEMARK ATTORNEYS 290 BURWOOD ROAD HAWTHORN VICTORIA 3122 AUSTRALIA CJH:DRM